key: cord-1039436-vkiym9ju authors: Mai, Aaron Shengting; Tan, Eng-King title: COVID-19 vaccination precipitating de novo ANCA-associated vasculitis: clinical implications date: 2022-01-27 journal: Clin Kidney J DOI: 10.1093/ckj/sfac026 sha: 6f6d1e4d438438c11060a66edd1239cb8e5572e6 doc_id: 1039436 cord_uid: vkiym9ju nan We read with great interest the article by Fillon et al. [1] discussing a matter of arising importance-the precipitation of vasculitis associated with coronavirus disease 2019 (COVID-19) vaccination. Vaccination against COVID-19 remains the cornerstone in our battle against the pandemic and the need for herd immunity becomes increasingly important with the emergence of new variants. Despite having a good safety profile, post-marketing surveillance has demonstrated that COVID-19 vaccines may result in rare but severe adverse reactions, such as myocarditis and thrombotic thrombocytopaenia. One major area of concern that has thus far received limited attention is the development of de novo autoimmune diseases following COVID-19 vaccination in previously well individuals. One such autoimmune condition, anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), warrants particular interest because its presenting complaints can be very nonspecific. AAV involves the inflammation of small blood vessels characterized by the presence of autoantibodies against the selfantigens in the cytoplasmic granules of neutrophils [2] . While the article by Fillon et al. [1] discusses four cases of relapsing AAV, another point of great interest that remains poorly studied is the precipitation of de novo AAV shortly after receipt of the COVID-19 vaccine. To address gaps in knowledge regarding the association between COVID-19 vaccination and new-onset AAV, we reviewed published reports from January 2020 to January 2022 to investigate the clinical presentations, associations and outcomes of new-onset AAV precipitated by COVID-19 vaccination. Cases were included if the patients had symptom onset within 2 weeks of a previous COVID-19 vaccine dose, fulfilled the American College of Rheumatology diagnostic criteria for AAV [3] [4] [5] , were previously undiagnosed with AAV and were treated with a reportable outcome. Our search found 13 cases fulfilling the criteria for de novo AAV occurring shortly after COVID-19 vaccination (Supplementary data, Table S1) [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] . Five cases presented with neurologic symptoms (such as headache, dizziness and even paraesthesia) [6, 8, 11, 16, 17] , four cases with fever and flu-like symptoms [6, 7, 15, 16] , four with weakness and fatigue [8, 11, 12, 16] , three with nausea and vomiting [8] [9] [10] and three with haemoptysis [9, 14, 17] . With the exception of three patients [6, 16, 18] , all remaining patients presented with acute kidney injury hallmarked by elevated serum creatinine, haematuria and proteinuria. Of interest, one patient presented with rhabdomyolysis [12] , two presented with symptoms of neuritis [6, 18] and another presented with acute necrotizing granulomatous inflammation of the lungs [16] . Two cases were also observed to have underlying autoimmune risk factors: one patient had mild asthma [6] , while another had seronegative arthritis and a 2-year history of undiagnosed vasculitis symptoms [8] . Eleven received a messenger RNA vaccine [6] [7] [8] [9] [10] [11] [12] [13] [16] [17] [18] , while two received a viral vector vaccine [14, 15] . AAV was precipitated in six patients after the first vaccine dose [7, 10, 14, 15, 17, 18] and in seven patients after the second [6, 8, 9, [11] [12] [13] 16] . Seven patients developed symptoms within 1 week after vaccination [6, 9, 13, 14, [16] [17] [18] , with five developing them within 2 weeks [8, [10] [11] [12] 15] ; the time to symptom onset was not reported for one patient [7] . All included cases were treated with steroid therapy; five patients were further treated with cyclophosphamide [7, 11, 12, 14, 15] , five with rituximab [6, 8, 10, 16, 17] and two with both [9, 13] . All recovered without fur-ther complications except for one patient who required chronic haemodialysis [11] . In conclusion, COVID-19 vaccination can be associated with the development of AAV in previously well patients, with the most common symptoms being fever, nausea and vomiting, non-specific neurological symptoms and malaise. The prevalence of post-vaccination new-onset AAV is comparable between the first and second dose and the prognosis is good following prompt treatment. Most importantly, physicians should have a high index of suspicion for AAV if patients develop the above-mentioned symptoms and screening for ANCA may be warranted. Supplementary data are available at ckj online. No new data were generated or analysed in support of this research. De novo and relapsing necrotizing vasculitis after COVID-19 vaccination ANCA glomerulonephritis and vasculitis The American College of Rheumatology 1990 criteria for the classification of hypersensitivity vasculitis The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis) Eosinophilic granulomatosis with polyangiitis after COVID-19 vaccination De novo vasculitis after mRNA-1273 (Moderna) vaccination De novo and relapsing glomerulonephritis following SARS-CoV-2 mRNA vaccination in microscopic polyangiitis De-novo antineutrophil cytoplasmic antibody-associated vasculitis following the mRNA-1273 (Moderna) vaccine for COVID-19 ANCA-associated vasculitis following Pfizer-BioNTech COVID-19 vaccine ANCA glomerulonephritis after the Moderna COVID-19 vaccination Case report: ANCA-associated vasculitis presenting with rhabdomyolysis and pauci-immune crescentic glomerulonephritis after Pfizer-BioNTech COVID-19 mRNA vaccination Antineutrophil cytoplasmic autoantibody-associated glomerulonephritis following the Pfizer-BioNTech COVID-19 vaccine A case of ANCAassociated vasculitis after AZD1222 -2 vaccination: casualty or causality? ANCA-associated vasculitis following Johnson and Johnson COVID-19 vaccine Association of COVID-19 antigenicity with the development of antineutrophilic cytoplasmic antibody vasculitis Case report: Antineutrophil cytoplasmic antibody-associated vasculitis with acute renal failure and pulmonary hemorrhage may occur after COVID-19 vaccination Myeloperoxidase anti-neutrophil cytoplasmic antibody positive optic perineuritis after mRNA coronavirus disease-19 vaccine None declared.